DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma

Rationale: Although sunitinib has been shown to improve the survival rate of advanced renal cell carcinoma (RCC) patients, poor drug response is a major challenge that reduces patient benefit. It is important to elucidate the underlying mechanism so that the therapeutic response to sunitinib can be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tangliang, Bao, Yi, Gan, Xinxin, Wang, Jie, Chen, Qiong, Dai, Zhihui, Liu, Bing, Wang, Anbang, Sun, Shuhan, Yang, Fu, Wang, Linhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735520/
https://www.ncbi.nlm.nih.gov/pubmed/31534544
http://dx.doi.org/10.7150/thno.35572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735520/
https://www.ncbi.nlm.nih.gov/pubmed/31534544
http://dx.doi.org/10.7150/thno.35572

Ejemplares similares